A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin in Subjects With Genotype 2 Hepatitis C, Who Relapsed After Previous Treatment.

Trial Profile

A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin in Subjects With Genotype 2 Hepatitis C, Who Relapsed After Previous Treatment.

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2015

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary) ; Telaprevir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 01 Jun 2012 Actual initiation date changed from Nov 2011 to May 2012, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top